![]() |
Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis
Kuei-Chuan Lee, Pei-Shan Wu, Han-Chieh Lin
Clin Mol Hepatol. 2023;29(1):77-98. Published online 2022 Oct 13 DOI: https://doi.org/10.3350/cmh.2022.0237
|
Citations to this article as recorded by
Diosgenin attenuates nonalcoholic fatty liver disease through mTOR-mediated inhibition of lipid accumulation and inflammation
Guoliang Yin, Hongyi Liang, Yiran Cheng, Suwen Chen, Xin Zhang, Decheng Meng, Wenfei Yu, Hongshuai Liu, Chaoyuan Song, Fengxia Zhang
Chemico-Biological Interactions.2025; 405: 111306. CrossRef Curcumol ameliorates alcohol and high-fat diet-induced fatty liver disease via modulation of the Ceruloplasmin/iron overload/mtDNA signaling pathway
Tingting Ding, Wanqing Shen, Wenhui Tao, Junlu Peng, Meijun Pan, Xiaoyu Qi, Wanyu Feng, Na Wei, Shuguo Zheng, Huanhuan Jin
The Journal of Nutritional Biochemistry.2025; 136: 109807. CrossRef Aqueous extract of Cornus officinalis alleviate NAFLD via protecting hepatocytes proliferation through regulation of the tricarboxylic acid cycle
Binjie Liu, Ting Shao, Dandan Xiao, Shujie Yang, Weijie Lin, Lizhu Sun, Weiqin Zhang, Meiqing Luo, Jinlan Zhao, Lei Yang, Shasha Bai, Di Deng, Caiyan Wang, Shaogui Wang, Rong Zhang, Zhongqiu Liu, Lin An
Journal of Ethnopharmacology.2025; 341: 119330. CrossRef SFAs facilitates ceramide’s de novo synthesis via TLR4 and intensifies hepatocyte lipotoxicity
Yuchao Zou, Lulu Tian, Liuhua Pei, Jie Hao, Tianhang Chen, Jiayu Qi, Jiannan Qiu, Yinuo Xu, Xiaokai Hu, Lin Chen, Xiaobing Dou
International Immunopharmacology.2025; 147: 114020. CrossRef Cepharanthine relieves nonalcoholic steatohepatitis through inhibiting STAT1/CXCL10 axis-mediated lipogenesis and inflammatory responses
Pan Li, Ruoyu Zhang, Pingping Hu, Tingting Wang, Jianwei Wang
Journal of Ethnopharmacology.2025; 341: 119358. CrossRef Hypertension and NAFLD risk: Insights from the NHANES 2017–2018 and Mendelian randomization analyses
Mengqin Yuan, Jian He, Xue Hu, Lichao Yao, Ping Chen, Zheng Wang, Pingji Liu, Zhiyu Xiong, Yingan Jiang, Lanjuan Li
Chinese Medical Journal.2024; 137(4): 457. CrossRef MicroRNA-582-3p knockdown alleviates non-alcoholic steatohepatitis by altering the gut microbiota composition and moderating TMBIM1
Shuo Huang, Xia Xiao, Hongman Wu, Feng Zhou, Chenchao Fu
Irish Journal of Medical Science (1971 -).2024; 193(2): 909. CrossRef From NAFLD to MASLD: When metabolic comorbidity matters
Shan Hong, Lei Sun, Yiwei Hao, Ping Li, Yuling Zhou, Xiuxia Liang, Julong Hu, Hongshan Wei
Annals of Hepatology.2024; 29(2): 101281. CrossRef Machine learning-based integration identifies the ferroptosis hub genes in nonalcoholic steatohepatitis
Longfei Dai, Wenkang Yuan, Renao Jiang, Zhicheng Zhan, Liangliang Zhang, Xinjian Xu, Yuyang Qian, Wenqi Yang, Zhen Zhang
Lipids in Health and Disease.2024;[Epub] CrossRef Meta‐analysis: Efficacy and safety of fibroblast growth factor 21 analogues for the treatment of non‐alcoholic steatohepatitis and non‐alcoholic steatohepatitis‐related fibrosis
Rutao Lin, Jianghua Zhou, Qinmei Sun, Xin Xin, Yiyang Hu, Minghua Zheng, Qin Feng
Alimentary Pharmacology & Therapeutics.2024; 59(7): 802. CrossRef Hepatic Stellate Cell‐Targeting Micelle Nanomedicine for Early Diagnosis and Treatment of Liver Fibrosis
Lei Wang, Jieying Zhou, Jian Wang, Xiaotang Wang, Haijuan Dong, Lingzhi Zhao, Junchen Wu, Juanjuan Peng
Advanced Healthcare Materials.2024;[Epub] CrossRef Effect of Blueberry Supplementation on a Diet-Induced Rat Model of Prediabetes—Focus on Hepatic Lipid Deposition, Endoplasmic Stress Response and Autophagy
Gonçalo Ferreira, Pedro Vieira, André Alves, Sara Nunes, Inês Preguiça, Tânia Martins-Marques, Tânia Ribeiro, Henrique Girão, Artur Figueirinha, Lígia Salgueiro, Manuela Pintado, Pedro Gomes, Sofia Viana, Flávio Reis
Nutrients.2024; 16(4): 513. CrossRef Liver-based inter-organ communication: A disease perspective
Xin-Yan Luo, Si-Qi Ying, Yuan Cao, Yan Jin, Fang Jin, Chen-Xi Zheng, Bing-Dong Sui
Life Sciences.2024; 351: 122824. CrossRef STUB1 increases adiponectin expression by inducing ubiquitination and degradation of NR2F2, thereby reducing hepatic stellate cell activation and alleviating non-alcoholic fatty liver disease
Zheng Mao, Jindong Zhao, Fan Cui, Zhen Li, Jinjin Cao, Jingjing Zhou, Mingliang Hou, Zengkun Qian
Tissue and Cell.2024; 88: 102345. CrossRef The Renin–Angiotensin System and Cardiovascular–Kidney–Metabolic Syndrome: Focus on Early-Life Programming
You-Lin Tain, Chien-Ning Hsu
International Journal of Molecular Sciences.2024; 25(6): 3298. CrossRef Dietary inflammatory index is associated with metabolic dysfunction-associated fatty liver disease among United States adults
Jing Yan, Jun Zhou, Yuanyuan Ding, Chuantao Tu
Frontiers in Nutrition.2024;[Epub] CrossRef Underlying Mechanisms behind the Brain–Gut–Liver Axis and Metabolic-Associated Fatty Liver Disease (MAFLD): An Update
Júlia Pauli De Cól, Enzo Pereira de Lima, Fernanda Moris Pompeu, Adriano Cressoni Araújo, Ricardo de Alvares Goulart, Marcelo Dib Bechara, Lucas Fornari Laurindo, Nahum Méndez-Sánchez, Sandra Maria Barbalho
International Journal of Molecular Sciences.2024; 25(7): 3694. CrossRef Immunopathogenesis of liver fibrosis in steatotic liver disease
Chaerin Woo, Won-Il Jeong
Clinical and Molecular Hepatology.2024; 30(2): 299. CrossRef Xiaozhi formula attenuates non-alcoholic fatty liver disease by regulating lipid metabolism via activation of AMPK and PPAR pathways
Liping You, Tao Wang, Wenxuan Li, Jinghao Zhang, Chao Zheng, Yanxi Zheng, Suyin Li, Zhi Shang, Jiacheng Lin, Fang Wang, Yihan Qian, Zhijia Zhou, Xiaoni Kong, Yueqiu Gao, Xuehua Sun
Journal of Ethnopharmacology.2024; 329: 118165. CrossRef Adherence to an antioxidant diet and lifestyle is associated with reduced risk of cardiovascular disease and mortality among adults with nonalcoholic fatty liver disease: evidence from NHANES 1999–2018
Yingzi Li, Yipin Liu
Frontiers in Nutrition.2024;[Epub] CrossRef Deciphering the molecular pathways of saroglitazar: A dual PPAR α/γ agonist for managing metabolic NAFLD
Devaraj Ezhilarasan
Metabolism.2024; 155: 155912. CrossRef Would Combination Be Better: Swimming Exercise and Intermittent Fasting Improve High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease in Obese Rats via the miR-122-5p/SREBP-1c/CPT1A Pathway
Kang Yang, Chengye Liu, Jun Shao, Lingxiang Guo, Qing Wang, Zhaoxiang Meng, Xing Jin, Xianghe Chen
Diabetes, Metabolic Syndrome and Obesity.2024; Volume 17: 1675. CrossRef Elucidating cuproptosis in metabolic dysfunction-associated steatotic liver disease
Yamei Li, Ping Qi, Si-Yuan Song, Yiping Wang, Hailian Wang, Peng Cao, Yu’e Liu, Yi Wang
Biomedicine & Pharmacotherapy.2024; 174: 116585. CrossRef Association of NAFLD/NASH, and MAFLD/MASLD with chronic kidney disease: an updated narrative review
Amedeo Lonardo
Metabolism and Target Organ Damage.2024;[Epub] CrossRef Role of Culinary Indian Spices in the Regulation of TGF‐β Signaling Pathway in Inflammation‐Induced Liver Cancer
Ajay Sarija Asoka, Anusha Kolikkandy, Bhagyalakshmi Nair, Adithya J. Kamath, Gautam Sethi, Lekshmi R. Nath
Molecular Nutrition & Food Research.2024;[Epub] CrossRef Unraveling the relationship between histone methylation and nonalcoholic fatty liver disease
Li Xu, Yu-Hong Fan, Xiao-Jing Zhang, Lan Bai
World Journal of Hepatology.2024; 16(5): 703. CrossRef Preventing High Fat Diet-Induced Obesity and Related Hepatic Steatosis by Chlorin e6-Mediated Photodynamic Therapy
Pallavi Gurung, Junmo Lim, Yong-Wan Kim
Pharmaceuticals.2024; 17(6): 729. CrossRef Leonurine: a comprehensive review of pharmacokinetics, pharmacodynamics, and toxicology
Siyu Liu, Chen Sun, Hailin Tang, Cheng Peng, Fu Peng
Frontiers in Pharmacology.2024;[Epub] CrossRef MAFLD Pandemic: Updates in Pharmacotherapeutic Approach Development
Farah Khaznadar, Omar Khaznadar, Ana Petrovic, Marija Hefer, Fabian Gjoni, Stefan Gjoni, Justinija Steiner, Martina Smolic, Kristina Bojanic
Current Issues in Molecular Biology.2024; 46(7): 6300. CrossRef Dual effects of Psoraleae Fructus on the liver: hepatoprotection or hepatoxicity?
Qianhui Tang, Qinwei Yu, Bin Ni, Zhenzhou Jiang, Luyong Zhang
Acupuncture and Herbal Medicine.2024; 4(2): 176. CrossRef Changes in alanine aminotransferase and body composition and metabolic factors among individuals receiving medical health checkups
Saori Onishi, Akira Fukuda, Masahiro Matsui, Kosuke Ushiro, Tomohiro Nishikawa, Akira Asai, Soo Ki Kim, Hiroki Nishikawa
Hepatology Research.2024; 54(12): 1193. CrossRef The use of traditional Chinese medicine in the treatment of non-alcoholic fatty liver disease: A review
Zhaolin Sun, Yuhua Wei, Yuchen Xu, Jianwei Jiao, Xiuying Duan
Pharmacological Research - Modern Chinese Medicine.2024; 12: 100475. CrossRef A comprehensive framework for managing metabolic dysfunction-associated steatotic liver disease: analyzing novel risk factors and advances in nanotechnology-based treatments and diagnosis
Lucia M. Chávez-López, Gabriela I. Carballo-López, Karina del Carmen Lugo-Ibarra, Ana B. Castro-Ceseña
RSC Medicinal Chemistry.2024; 15(8): 2622. CrossRef Gut microbiota changes and novel markers associated with liver steatosis in obese patients
Kh.A. Moskva, O.P. Kikhtyak, M.O. Kondratyuk, M.L. Farmaha, Ya.L. Leshchuk, S.I. Fediaieva, Ye.S. Leshchuk, T.A. Kikhtiak
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine).2024; 20(3): 179. CrossRef Usefulness of Body Fat and Visceral Fat Determined by Bioimpedanciometry versus Body Mass Index and Waist Circumference in Predicting Elevated Values of Different Risk Scales for Non-Alcoholic Fatty Liver Disease
María Gordito Soler, Ángel Arturo López-González, Daniela Vallejos, Emilio Martínez-Almoyna Rifá, María Teófila Vicente-Herrero, José Ignacio Ramírez-Manent
Nutrients.2024; 16(13): 2160. CrossRef Research Progress of Porphyrin Metabolism in Fatty Liver Disease
雯 郭
Advances in Clinical Medicine.2024; 14(07): 321. CrossRef Bariatric intervention improves metabolic dysfunction-associated steatohepatitis in patients with obesity: A systematic review and meta-analysis
Juchul Hwang, Hyeyoung Hwang, Hyunjae Shin, Bo Hyun Kim, Seong Hee Kang, Jeong-Ju Yoo, Mi Young Choi, Dong eun Lee, Dae Won Jun, Yuri Cho
Clinical and Molecular Hepatology.2024; 30(3): 561. CrossRef Association between SII and markers of liver injury: A cross-sectional study from the NHANES (2017–2020)
Xu-Feng Zhang, Yu-Yan Qin, Miguel Marcos
PLOS ONE.2024; 19(7): e0303398. CrossRef Atf3-mediated metabolic reprogramming in hepatic macrophage orchestrates metabolic dysfunction–associated steatohepatitis
Shuwei Hu, Rui Li, Dongxu Gong, Pei Hu, Jitu Xu, Yingjie Ai, Xiaojie Zhao, Chencheng Hu, Minghuan Xu, Chenxi Liu, Shuyu Chen, Jie Fan, Zhonghua Zhao, Zhigang Zhang, Huijuan Wu, Yanyong Xu
Science Advances.2024;[Epub] CrossRef Tetrahydrocurcumin ameliorates hepatic steatosis by restoring hepatocytes lipophagy through mTORC1-TFEB pathway in nonalcoholic steatohepatitis
Jiazhen Wu, Fengkun Guan, Haipiao Huang, Hanbin Chen, Yuhong Liu, Shangbin Zhang, Muxia Li, Jianping Chen
Biomedicine & Pharmacotherapy.2024; 178: 117297. CrossRef Noncoding RNA-Mediated Epigenetic Regulation in Hepatic Stellate Cells of Liver Fibrosis
Ruoyu Gao, Jingwei Mao
Non-Coding RNA.2024; 10(4): 44. CrossRef Tanshinone IIA Inhibits the Endoplasmic Reticulum Stress-Induced Unfolded Protein Response by Activating the PPARα/FGF21 Axis to Ameliorate Nonalcoholic Steatohepatitis
Dajin Pi, Zheng Liang, Jinyue Pan, Jianwei Zhen, Chuiyang Zheng, Wen Fan, Qingliang Song, Maoxing Pan, Qinhe Yang, Yupei Zhang
Antioxidants.2024; 13(9): 1026. CrossRef Experimental models of fibrosis
Vadim A. Kosolapov, Roman A. Litvinov, Alexander A. Spasov
Journal of Volgograd State Medical University.2024; 21(3): 39. CrossRef Serum follistatin like 1 in children with obesity and metabolic-associated fatty liver disease
Lujie Liu, Meng Li, Yujie Qin, Luyang Liu, Yanfeng Xiao
BMC Endocrine Disorders.2024;[Epub] CrossRef Emerging mechanisms of non-alcoholic steatohepatitis and novel drug therapies
Hao CHEN, Yang ZHOU, Haiping HAO, Jing XIONG
Chinese Journal of Natural Medicines.2024; 22(8): 724. CrossRef Clinical application of cluster analysis in patients with newly diagnosed type 2 diabetes
Yazhi Wang, Hui Chen
Hormones.2024;[Epub] CrossRef Serum isthmin-1 is a potential biomarker for metabolic dysfunction associated fatty liver disease in patients with metabolic syndrome and type 2 diabetes mellitus
Xiaohui Lei, HaiYan Chen, YuXin Xu, Zhuoran Yang, Lili Zhang, Cong Wang, Hu Du
BMJ Open Diabetes Research & Care.2024; 12(5): e004514. CrossRef Incretin-based therapy in the management of metabolic dysfunction-associated steatotic liver disease (MASLD): one piece of the puzzle: Editorial on “Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fa
Tian-Yi Ren, Mohammed Eslam, Jian-Gao Fan
Clinical and Molecular Hepatology.2024; 30(4): 649. CrossRef Advances in the understanding of the role and mechanism of action of PFKFB3‑mediated glycolysis in liver fibrosis (Review)
Qian Liu, Jiajia Li, Xin Li, Li Zhang, Shun Yao, Yongfeng Wang, Biguang Tuo, Hai Jin
International Journal of Molecular Medicine.2024;[Epub] CrossRef КЛІНІЧНИЙ ПРОФІЛЬ ПАЦІЄНТІВ ІЗ НЕАЛКОГОЛЬНОЮ ЖИРОВОЮ ХВОРОБОЮ ПЕЧІНКИ ТА ІНСУЛІНОРЕЗИСТЕНТНІСТЮ
О. А. Козак
Здобутки клінічної і експериментальної медицини.2024; (3): 47. CrossRef The correlation between non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio (NHHR) with non-alcoholic fatty liver disease: an analysis of the population-based NHANES (2017–2018)
Yuhao Yang, Shengxi Li, Zhenmei An, Shuangqing Li
Frontiers in Medicine.2024;[Epub] CrossRef Pathogenesis and management of metabolic dysfunction-associated
steatohepatitis-related hepatocellular carcinoma: a narrative
review
Han Ah Lee
The Ewha Medical Journal.2024;[Epub] CrossRef Association between advanced fibrosis and epigenetic age acceleration among individuals with MASLD
Haili Wang, Zhenqiu Liu, Hong Fan, Chengnan Guo, Xin Zhang, Yi Li, Suzhen Zhao, Luojia Dai, Ming Zhao, Tiejun Zhang
Journal of Gastroenterology.2024;[Epub] CrossRef Regulation of Inflammation, Lipid Metabolism, and Liver Fibrosis by Core Genes of M1 Macrophages in NASH
Xingyu Xu, Yaqin Dong, Jianjun Liu, Peng Zhang, Wenqi Yang, Longfei Dai
Journal of Inflammation Research.2024; Volume 17: 9975. CrossRef Ganoderma lucidum Spore Powder Alleviates Metabolic-Associated Fatty Liver Disease by Improving Lipid Accumulation and Oxidative Stress via Autophagy
Yuxuan Zhang, Jiali Zhou, Lan Yang, Hang Xiao, Dongbo Liu, Xincong Kang
Antioxidants.2024; 13(12): 1501. CrossRef Role of MMP-2 and MMP-9 in the Relationship between Inflammation, Fibrosis, and Apoptosis during Progression of Non-Alcoholic Fatty Liver Disease and Diagnostic Significance of Plasma Levels of Their Active Forms
Irina V. Kurbatova, Lyudmila V. Topchieva, Olga P. Dudanova, Anastasia A. Shipovskaya
Biochemistry (Moscow).2024; 89(11): 1998. CrossRef The moderating effect of dietary fiber intake on the association between sleep pattern and liver fibrosis in metabolic dysfunction-associated steatotic liver disease: a study from NHANES
Guoqing Jia, Mengzhen Jia, Chuntao Li
BMC Gastroenterology.2024;[Epub] CrossRef Pharmacotherapy of Liver Fibrosis and Hepatitis: Recent Advances
Liangtao Zhao, Haolan Tang, Zhangjun Cheng
Pharmaceuticals.2024; 17(12): 1724. CrossRef Ultrasonographic findings in female inmates in a prison unit in the state of São Paulo, Brazil
Soraya Gomes de Amorim Andrade, Fernando Moreira de Andrade, Edward Araujo Júnior, Wagner José Gonçalves, José Mendes Aldrighi
Radiologia Brasileira.2024;[Epub] CrossRef Neuregulin 4 as a novel adipokine in energy metabolism
Yuanbin Liu, Mingkai Chen
Frontiers in Physiology.2023;[Epub] CrossRef Noninvasive serum biomarkers for liver fibrosis in NAFLD: current and future
Tina Reinson, Ryan M. Buchanan, Christopher D. Byrne
Clinical and Molecular Hepatology.2023; 29(Suppl): S157. CrossRef Immunotherapy for NAFLD and NAFLD-related hepatocellular carcinoma
Seogsong Jeong, Woo-Young Shin, Yun Hwan Oh
Frontiers in Endocrinology.2023;[Epub] CrossRef A Combination of an Angiotensin II Receptor and a Neprilysin Inhibitor Attenuates Liver Fibrosis by Preventing Hepatic Stellate Cell Activation
Junya Suzuki, Kosuke Kaji, Norihisa Nishimura, Takahiro Kubo, Fumimasa Tomooka, Akihiko Shibamoto, Satoshi Iwai, Yuki Tsuji, Yukihisa Fujinaga, Koh Kitagawa, Tadashi Namisaki, Takemi Akahane, Hitoshi Yoshiji
Biomedicines.2023; 11(5): 1295. CrossRef In Vivo and In Vitro Models to Study Liver Fibrosis: Mechanisms and Limitations
Young-Sun Lee, Ekihiro Seki
Cellular and Molecular Gastroenterology and Hepatology.2023; 16(3): 355. CrossRef Non-alcoholic fatty liver disease: Immunological mechanisms and current treatments
Lucy Petagine, Mohammed Gulrez Zariwala, Vinood B Patel
World Journal of Gastroenterology.2023; 29(32): 4831. CrossRef Obeticholic acid treatment of mice to promote fertilization and reproduction
Ming Liang, Huailiang Yang, Lanyong Xu, Longqiao Cao
Zygote.2023; 31(6): 527. CrossRef Non-Alcoholic Fatty Liver Disease and Echocardiographic Parameters of Left Ventricular Diastolic Function: A Systematic Review and Meta-Analysis
Athina Goliopoulou, Panagiotis Theofilis, Evangelos Oikonomou, Artemis Anastasiou, Panteleimon Pantelidis, Maria Ioanna Gounaridi, Georgios E. Zakynthinos, Ourania Katsarou, Eva Kassi, Vaia Lambadiari, Dimitris Tousoulis, Manolis Vavuranakis, Gerasimos Si
International Journal of Molecular Sciences.2023; 24(18): 14292. CrossRef Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus-faced modernity
Gi-Ae Kim, Joon Ho Moon, Won Kim
Clinical and Molecular Hepatology.2023; 29(4): 831. CrossRef Dietary and lifestyle oxidative balance scores are independently and jointly associated with nonalcoholic fatty liver disease: a 20 years nationally representative cross-sectional study
Yuanbin Liu, Mingkai Chen
Frontiers in Nutrition.2023;[Epub] CrossRef Naringin ameliorates liver fibrosis in zebrafish by modulating IDO1-mediated lipid metabolism and inflammatory infiltration
Meng-chen Qin, Jun-jie Li, Yan-tao Zheng, Yun-jia Li, Yu-xue Zhang, Rou-xuan Ou, Wei-yi He, Jia-min Zhao, Su-tong Liu, Ming-hao Liu, Hai-yan Lin, Lei Gao
Food & Function.2023; 14(23): 10347. CrossRef Association between nonalcoholic fatty liver disease and type 2 diabetes: A bidirectional two-sample mendelian randomization study
Xuetong Ni, Chao Tong, Aheyeerke Halengbieke, Tengrui Cao, Jianmin Tang, Lixin Tao, Deqiang Zheng, Yumei Han, Qiang Li, Xinghua Yang
Diabetes Research and Clinical Practice.2023; 206: 110993. CrossRef Therapeutics for Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)
Kamlesh K. Bhopale, Mukund P. Srinivasan
Livers.2023; 3(4): 597. CrossRef Mitochondrial Dysfunction in Metabolic Dysfunction Fatty Liver Disease (MAFLD)
Ying Zhao, Yanni Zhou, Dan Wang, Ziwei Huang, Xiong Xiao, Qing Zheng, Shengfu Li, Dan Long, Li Feng
International Journal of Molecular Sciences.2023; 24(24): 17514. CrossRef Inducible nitric oxide synthase accelerates nonalcoholic fatty liver disease progression by regulating macrophage autophagy
Guiyuan Jin, Xiaoying Yao, Dong Liu, Juan Zhang, Xiaobei Zhang, Yonghong Yang, Yanzhen Bi, Hui Zhang, Guanjun Dong, Huixin Tang, Shumin Cheng, Feng Hong, Meng Si
Immunity, Inflammation and Disease.2023;[Epub] CrossRef Non-Alcoholic Fatty Liver Disease, Atherosclerosis, and Cardiovascular Disease in Asia
Yohwan Lim, Seogsong Jeong, Myunghee Hong, Hyun Wook Han
Reviews in Cardiovascular Medicine.2023;[Epub] CrossRef Principales fonctions hépatiques
M. Maitre, C. Klein
EMC - Hépatologie.2023; 38(4): 1. CrossRef
|